Tuesday, October 21, 2008

Under attack!

Ranbaxy won’t be affected much

Daiichi’s acquisition of the Indian Pharmaceutical giant Ranbaxy Laboratories Ltd. has stirred the hornet’s nest in the pharma industry.Ranbaxy won’t be affected much And the talks about the deal haven’t even died down when Ranbaxy has to face yet another glitch in the form of adulteration charges in its drugs from the US authorities: the Food and Drug Administration and Department of Justice. Ranbaxy’s stock faced a severe knocking since, falling by 18% to Rs.437 as on July 18, compared to Rs.538 on July 10, when the controversy broke.

It was a foregone conclusion that Big Pharma would not be happy with the deal, which merges a generic giant with an R&D major. But the matter became more complicated due to the statement made by Malvinder Singh, Chairman & CEO, Ranbaxy, to the press on July 18, when he said, “All these issues have emerged after the deal with Daiichi Sankyo... an MNC is trying to derail Ranbaxy’s deal with Daiichi Sankyo.”...Continue

Source : IIPM Editorial, 2008
An Initiative of IIPM, Malay Chaudhuri and Arindam chaudhuri (Renowned Management Guru and Economist).

Read also :-